J
Jun Zhang
Researcher at Mayo Clinic
Publications - 147
Citations - 5615
Jun Zhang is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 37, co-authored 129 publications receiving 4611 citations. Previous affiliations of Jun Zhang include Hiroshima University & Chinese Academy of Sciences.
Papers
More filters
Journal ArticleDOI
CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis
Ting Zhang,Yan Zhang,Mingyao Cui,Li Jin,Yimei Wang,Fengxiang Lv,Yuli Liu,Wen Zheng,Haibao Shang,Jun Zhang,Mao Zhang,Hong-Kun Wu,Jiaojiao Guo,Xiuqin Zhang,Xinli Hu,Chun-Mei Cao,Rui-Ping Xiao +16 more
TL;DR: It is shown that receptor-interacting protein 3 (RIP3) triggers myocardial necroptosis, in addition to apoptosis and inflammation, through activation of Ca2+-calmodulin–dependent protein kinase (CaMKII) rather than through the well-established RIP3 partners RIP1 and MLKL.
Journal ArticleDOI
Intrinsic BET inhibitor resistance in SPOP -mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
Pingzhao Zhang,Dejie Wang,Yu Zhao,Shancheng Ren,Kun Gao,Zhenqing Ye,Shangqian Wang,Chun Wu Pan,Yasheng Zhu,Yuqian Yan,Yinhui Yang,Di Wu,Yundong He,Jun Zhang,Daru Lu,Xiuping Liu,Long Yu,Shimin Zhao,Yao Li,Dong Lin,Yuzhuo Wang,Liguo Wang,Yu Chen,Yinghao Sun,Chenji Wang,Haojie Huang +25 more
TL;DR: It is demonstrated that wild-type SPOP binds to and induces ubiquitination and proteasomal degradation of BET proteins by recognizing a degron motif common among them, and resistance to BET inhibitors in SPOP-mutant prostate cancer can be overcome by combination with AKT inhibitors.
Journal ArticleDOI
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp,Jesse S. Voss,Sarah E. Kerr,Emily G. Barr Fritcher,Rondell P. Graham,Lizhi Zhang,W. Edward Highsmith,Jun Zhang,Lewis R. Roberts,Gregory J. Gores,Kevin C. Halling +10 more
TL;DR: The results of this study show for the first time that isocitrate dehydrogenase 1 and 2 genes are mutated in cholangiocarcinoma, which identifies a new potential target for genotype-directed therapeutic trials and may represent a potential biomarker for earlier detection of cholangsiocARCinoma in a subset of cases.
Journal ArticleDOI
Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.
Sofia Asioli,Lori A. Erickson,Thomas J. Sebo,Jun Zhang,Long Jin,Geoffrey B. Thompson,Ricardo V. Lloyd +6 more
TL;DR: PTC with a prominent hobnail pattern is a moderately differentiated PTC variant with aggressive clinical behavior and significant mortality.
Journal ArticleDOI
LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
TL;DR: Using EZH2 antibody-based RNA immunoprecipitation-coupled high throughput sequencing, it is demonstrated that EZh2 binds to MALAT1, a long non-coding RNA (lncRNA) that is overexpressed during PCa progression and that MALat1 plays a vital role in EzH2-enhanced migration and invasion in CRPC cell lines.